Drug intelligence / Profile preview

2A4

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

2A4 is a monoclonal antibody designed for the imaging and immunotherapy of AL amyloidosis. It specifically binds to a cryptic epitope found on amyloid fibrils, which is derived from a cleavage site of serum amyloid protein A (sAA) and contains a -Glu-Asp- amino acid pairing. Additionally, 2A4 demonstrates high-affinity binding to amyloid fibrils composed of immunoglobulin light chains. Studies have shown that radiolabeled 2A4 can specifically localize with human AL amyloid extracts, and treatment with 2A4 expedited the regression of ALκ amyloidomas in mice, likely mediated by macrophages and neutrophils.

Targets

AL (Amyloid light-chain protein)

Beyond the preview

Go deeper on 2A4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2A4.

Explore the full profile